Browse CLEC4M

Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane Single-pass type II membrane protein ; SUBCELLULAR LOCATION: Isoform 2: Cell membrane Single-pass type II membrane protein ; SUBCELLULAR LOCATION: Isoform 3: Cell membrane Single-pass type II membrane protein ; SUBCELLULAR LOCATION: Isoform 5: Secreted ; SUBCELLULAR LOCATION: Isoform 6: Secreted ; SUBCELLULAR LOCATION: Isoform 7: Secreted ; SUBCELLULAR LOCATION: Isoform 10: Secreted
Domain PF00059 Lectin C-type domain
Function

Probable pathogen-recognition receptor involved in peripheral immune surveillance in liver. May mediate the endocytosis of pathogens which are subsequently degraded in lysosomal compartments. Is a receptor for ICAM3, probably by binding to mannose-like carbohydrates. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for Ebolavirus. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for Hepatitis C virus. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for HIV-1. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for Human coronavirus 229E. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for Human cytomegalovirus/HHV-5. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for Influenzavirus. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for SARS coronavirus. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for West-nile virus. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for Japanese encephalitis virus. ; FUNCTION: (Microbial infection) Acts as an attachment receptor for Marburg virus glycoprotein. ; FUNCTION: (Microbial infection) Recognition of M.bovis by dendritic cells may occur partially via this molecule.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0007159 leukocyte cell-cell adhesion
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0008037 cell recognition
GO:0009988 cell-cell recognition
GO:0015833 peptide transport
GO:0019048 modulation by virus of host morphology or physiology
GO:0019058 viral life cycle
GO:0019062 virion attachment to host cell
GO:0019079 viral genome replication
GO:0019882 antigen processing and presentation
GO:0030193 regulation of blood coagulation
GO:0030260 entry into host cell
GO:0035821 modification of morphology or physiology of other organism
GO:0042886 amide transport
GO:0044003 modification by symbiont of host morphology or physiology
GO:0044406 adhesion of symbiont to host
GO:0044409 entry into host
GO:0044650 adhesion of symbiont to host cell
GO:0044766 multi-organism transport
GO:0046718 viral entry into host cell
GO:0046794 transport of virus
GO:0046968 peptide antigen transport
GO:0048002 antigen processing and presentation of peptide antigen
GO:0050817 coagulation
GO:0050818 regulation of coagulation
GO:0050878 regulation of body fluid levels
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0061041 regulation of wound healing
GO:0075733 intracellular transport of virus
GO:1900046 regulation of hemostasis
GO:1902579 multi-organism localization
GO:1902581 multi-organism cellular localization
GO:1902583 multi-organism intracellular transport
GO:1903034 regulation of response to wounding
Molecular Function GO:0001618 virus receptor activity
GO:0003823 antigen binding
GO:0005537 mannose binding
GO:0030246 carbohydrate binding
GO:0030369 ICAM-3 receptor activity
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042605 peptide antigen binding
GO:0046790 virion binding
GO:0048029 monosaccharide binding
GO:0048306 calcium-dependent protein binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
Reactome -
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CLEC4M and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CLEC4M in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CLEC4M in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.490.186
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4990.467
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4860.404
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9370.217
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.1620.335
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.650.648
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.0720.338
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5450.751
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.8990.336
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.510.473
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.510.6
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3140.394
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CLEC4M in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CLEC4M. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CLEC4M. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CLEC4M.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CLEC4M. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CLEC4M expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CLEC4M and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCLEC4M
NameC-type lectin domain family 4, member M
Aliases HP10347; DC-SIGNR; LSIGN; DCSIGNR; DC-SIGN2; CD209L; CD299; CD299 antigen; L-SIGN; CD209 antigen-like protei ......
Chromosomal Location19p13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CLEC4M collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.